RxDoctor Payments Data

Andrew Dranchak, NP

Psychiatric/Mental Health · Indianapolis, INNPI 1104436161

Payments from drug & device makers

$1,325in general payments, 2019–2025

Across 28 payments — averaging $47.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$664
  • Neurocrine Biosciences, Inc.$240
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$197
  • Takeda Pharmaceuticals U.S.A., Inc.$113
  • Otsuka America Pharmaceutical, Inc.$78
  • Vanda Pharmaceuticals Inc.$17
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,16688%
  • Education$15912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,325 in reported general payments places this provider in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$16,886
Medicare patients
63
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate36$310,489
Austedo XrDeutetrabenazine42$266,674
Invega SustennaPaliperidone Palmitate66$218,125
Invega TrinzaPaliperidone Palmitate11$103,509
RexultiBrexpiprazole51$87,434
VraylarCariprazine Hcl32$47,761
LybalviOlanzapine/Samidorphan Malate29$47,275
Abilify MaintenaAripiprazole14$35,733
Paliperidone ErPaliperidone44$24,802
TrintellixVortioxetine Hydrobromide39$18,283
Lurasidone Hcl21$10,494
Aripiprazole98$8,716
VyvanseLisdexamfetamine Dimesylate19$7,503
FetzimaLevomilnacipran Hcl13$6,411
Ramelteon43$6,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$664$321,63477 claims
Neurocrine Biosciences, Inc.Ingrezza$240$310,48936 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$78$123,16765 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$113$25,78658 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →